Case Report : Sorafenib-Induced Interstitial Pneumonitis in a Patient with Hepatocellular Carcinoma

Sorafenib is an oral multikinase inhibitor that has shown a survival benefit in patients with advanced hepatocellular carcinoma, and is considered to be generally safe. We treated a patient with interstitial lung disease that was associated with sorafenib therapy for the treatment of advanced hepato...

Full description

Saved in:
Bibliographic Details
Published in:Gut and liver 2010-12, Vol.4 (4), p.543
Main Authors: Hyung Joon Myung, Sook Hyang Jeong, Jin Wook Kim, Hee Sup Kim, Je Hyuck Jang, Ho Il Yoon, Jae Sung Kim
Format: Article
Language:Korean
Subjects:
Adverse effect
Chemotherapy
Hepatocellular carcinoma
Interstitial Lung disease
Sorafenib
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Sorafenib is an oral multikinase inhibitor that has shown a survival benefit in patients with advanced hepatocellular carcinoma, and is considered to be generally safe. We treated a patient with interstitial lung disease that was associated with sorafenib therapy for the treatment of advanced hepatocellular carcinoma. A 74-year-old man with hepatitis-C-virus-related hepatocellular carcinoma was treated with sorafenib. After 8 days of sorafenib administration, he received radiation therapy for an intrahepatic tumor located in segment eight. On the 24th day of sorafenib treatment, the patient developed acute interstitial pneumonitis that rapidly improved after the discontinuation of sorafenib and treatment with high-dose steroids. This case alerts physicians to the possibility of sorafenib-induced interstitial lung disease. (Gut Liver 2010;4:543-546)
ISSN:1976-2283